Now live: Pro — the full 13F research suite for serious investorsSee pricing →
JOHNSON & JOHNSON (JNJ)

Q2 2024 · 13F-HR

JOHNSON & JOHNSON (JNJ)holdings as filed

Filed 2024-08-09 · accession 0000904454-24-000451

$400.7M
Reported value
20
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74366E102PTGXProtagonist Therapeutics Inc.$84.9M21.2%2,449,183CommonSHARED
75383L102RAPPRapport Therapeutics, Inc.$58.1M14.5%2,498,051CommonSHARED
126638105CVRXCVRx, Inc.$49.2M12.3%4,103,430CommonSHARED
52490G102LEGNLegend Biotech Corporation$36.1M9.00%814,586CommonSHARED
21217B100CTNMContineum Therapeutics Inc.$34.9M8.70%1,979,173CommonSHARED
63009J107NBTXNanobiotix S.A.$28.1M7.02%5,623,816CommonSHARED
G59665102MGTXMeiraGTx Holdings plc$28.0M6.98%6,641,064CommonSHARED
74276L105PRCTProcept BioRobotics Corporation$21.9M5.46%357,939CommonSHARED
640979100NMRANeumora Therapeutics, Inc.$18.2M4.54%1,849,445CommonSHARED
98401F105XNCRXencor, Inc.$14.2M3.53%748,062CommonSHARED
31189P102FATEFate Therapeutics, Inc.$11.1M2.77%3,379,064CommonSHARED
04280A100ARWRArrowhead Pharmaceuticals, Inc.$6.4M1.61%247,598CommonSHARED
75120L100Rallybio Corporation$4.9M1.22%3,636,363CommonSHARED
M70700105NNOXNano-X Imaging Ltd.$1.2M0.29%158,852CommonSHARED
929033108Vor Biopharma, Inc.$1.1M0.27%1,074,658CommonSHARED
01438T106ALDXAldeyra Therapeutics, Inc.$991,9040.25%299,669CommonSHARED
09090D103BiomX Inc.$646,3880.16%1,923,201CommonSHARED
34385P108LABStandard BioTools Inc$552,1820.14%311,967CommonSHARED
007002108TORCEURAdicet Bio, Inc.$441,0110.11%364,472CommonSHARED
81727U105SENS1GBPSenseonics Holdings, Inc.$21,7940.01%54,621CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.